THE BIOLOGICAL ACTIVITY OF SODIUM DICHLOROACETATE AND ITS EFFECTIVENESS DURING THE EXPERIMENTAL CLINICAL STUDIES
https://doi.org/10.25207/1608-6228-2017-2-151-162
Abstract
Over 1400 papers in foreign publications are dealing with the research of the biological activity of sodium dichloroacetate. Meanwhile in the domestic scientific literature the present review is the first one and has the purpose to unite and systematize the results of numerous studies of its effects in vitro on different cell lines and experimental models as well as on the whole organism with the broad spectrum of pathological conditions and disorders accompanied by the mitochondrial dysfunction. The mechanism of its effect is connected with the activation of the pyruvatdehydrogenase complex that causes the optimization of the oxygen consumption and the decrease in the acidification level of environment in normal cells in conditions of the tissue hypoxemia which enables us to label it as a metabolic cytoprotector. In atypical cells the result is present as the metabolic inversion with the intensification of free-radical processes as well as the activation of the caspase enzyme cascade, the activity decrease of proproliferative and proangiogenetic transcriptional factors which explains the positive effect in treatment of a whole number of tumours.
About the Authors
I. Y. TSYMBALYUK
FSBEI HE KubSMU of the Ministry of Public Health Care of Russia
Russian Federation
Russian Federation
Department of Surgery № 2, the Faculty of Advanced Training and Occupational Retraining of Personnel
Russia, 350063, Krasnodar, Sedin Street 4
A. M. MANUILOV
FSBEI HE KubSMU of the Ministry of Public Health Care of Russia
Russian Federation
Russian Federation
Department of Surgery № 2, the Faculty of Advanced Training and Occupational Retraining of Personnel
Russia, 350063, Krasnodar, Sedin Street 4
K. A. POPOV
FSBEI HE KubSMU of the Ministry of Public Health Care of Russia
Russian Federation
Russian Federation
department of Fundamental and clinical biochemistry
Russia, 350063, Krasnodar, Sedin Street 4
F. U. KHUBIEVA
FSBEI HE KubSMU of the Ministry of Public Health Care of Russia
Russian Federation
Russian Federation
Department of Surgery № 2, the Faculty of Advanced Training and Occupational Retraining of Personnel
Russia, 350063, Krasnodar, Sedin Street 4
E. E. GILEVA
BI PHC “MCH № 1”
Russian Federation
Russian Federation
department of endocrinology
Russia, 350000, Krasnodar, Krasnaya Street, 103/Dlinnaya Street, 123, tel.+7 (928) 430-07-69
References
1. Васляева С. Н., Люсов В. А., Цыганкова О. В., Гордеев И. Г., Волов Н. А. Безболевая ишемия миокарда: патогенетические и патофизиологические механизмы. Традиционные и метаболические аспекты терапии // Российский кардиологический журнал. – 2004. – № 4(48). – С. 74-83.
2. Мануйлов А. М., Попов К. А., Цымбалюк И. Ю., Литвинова М. Г., Хубиева Ф. У. Шестопалов А. В. Биологическая активность дихлорацетата натрия: концепции и механизмы (обзор литературы) // Кубанский научный медицинский вестник. – 2016. – № 6 (161). – С. 156–163.
3. Сорокіна Л., Бiлюк А., Хижняк С. Вплив натрій дихлорацетату на перебіг проокисно- антиоксидантних процесів в організмі мишей з саркомою 37 // Бiологiя. – 2011. – Випуск 57. – С. 35–37.
4. Сорокіна Л. В., Хижняк С. В., Дiденко Г. В., Степанова Л. I., Капля О. А. Структурний стан клітинних мембран саркоми 37 в динаміці росту // Фiзика живого. – 2010. – Т. 18. № 3. – С. 83–88.
5. Archer S. L., Weir E. K., Wilkins M. R. The basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies // Circulation. – 2010. – Vol. 121. № 18. – P. 2045–2066.
6. Barsan W. G. Treatment of cerebral ischemia with dichloroacetate // United States Patent Number: 4,631,294. – Date of Patent: Dec. 23, 1986. – Appl. No.: 752,091. – Filed: Jul. 5, 1985.
7. Bonnet S., Archer S. L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R. et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth // Cancer Cell. – 2007. – Vol. 11. № 1. – P. 37–51.
8. Brandsma D., Dorlo T. P., Haanen J. H., Beijnen J. H., Boogerd W. Severe encephalopathy and polyneuropathy induced by dichloroacetate // Journal of Neurology. – 2010. – Vol. 257. № 12. – P. 2099–2100.
9. Cao W., Yacoub S., Shiverick K. T., Namiki K., Sakai Y., Porvasnik S. et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation // The Prostate. – 2008. – Vol. 68. № 11. – P. 1223–1231.
10. De Stefano N., Matthews P. M., Ford B. et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders // Neurology. – 1995. – Vol.45. № 6. – P. 1193–1198.
11. Dhar S., Lippard S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate // Proceedings of the National Academy of Sciences of the United States of America. – 2009. – Vol. 106. № 52. – P. 22199–22204.
12. Duncan G. E., Perkins L. A., Theriaque D. W., Neiberger R. E., Stacpoole P. W. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism // The Journal of Clinical Endocrinology & Metabolism. – 2004. – Vol. 89. № 4. – P. 1733– 1738.
13. Fereidoonnezhad M., Faghih Z., Mojaddami A., Tabaei S. M. H., Rezaei Z. Novel approach synthesis, molecular docking and cytotoxic activity evaluation of N-phenyl-2,2- dichloroacetamide derivatives as anticancer agents // Journal of Sciences, Islamic Republic of Iran. – 2016. – Vol. 27. № 1. – P. 39–49.
14. Fiebiger W., Olszewski U., Ulsperger E., Geissler K., Hamilton G. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines // Clinical & translational oncology. – 2011. – Vol. 13. № 1. – P. 43–49.
15. Flavin D. Medullary thyroid carcinoma relapse reversed with dichloroacetate: a case report // Oncology Letters. – 2010. – Vol. 1. № 5. – P. 889–891.
16. Heshe D., Hoogestraat S., Brauckmann C., Karst U., Boos J., Lanvers-Kaminsky C. Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs // Cancer Chemotherapy and Pharmacology. – 2011. – Vol. 67. № 3. – P. 647–655.
17. Ishiguro T., Ishiguro R., Ishiguro M., Iwai S. Co-treatment of dichloroacetate and omeprazole dramatically reduced the pain of pancreatic and bile duct cancer; possible blockade of their invasion // Abdominal Oncology. – 2013. – Vol. 1. – P. 1–4.
18. Ishiguro T., Ishiguro R., Ishiguro M., Iwai S. Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report // Hepatogastroenterology. – 2012. – Vol. 59. № 116. – P. 994–996.
19. Jung G. -S., Jeon J. -H., Choi Y. -K., Jang S. Y., Park S. Y., Kim S. -W., Byun J. -K., Kim M. -K., Lee S., Shin E. -C., Lee I. -K., Kang Y. N., Park K. -G. Pyruvate dehydrogenase kinase regulates hepatitis C virus replication // Scientific Reports. – 2016. – Vol. 6. – Article number 30846.
20. Kaufmann P., Engelstad K., Wei Y., Jhung S., Sano M. C., Shungu D. C. et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial // Neurology. – 2006. – Vol. 66. № 3. – P. 324–330.
21. Khan A. Case report of long term complete remission of metastatic renal squamous cell carcinoma after palliative radiotherapy and adjuvant dichloroacetate // Advances in Cancer: Research & Treatment. – 2012. – Vol. 2012. – Article ID 441895.
22. Khan A. Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report // Journal of Palliative Medicine. – 2011. – Vol. 14. № 8. – P. 973–977.
23. Kinnaird A., Dromparis P., Haromy A., Bowers L., Hashimoto K., Sutendra G. et al. Dichloroacetate is a novel therapy for renal cell carcinoma // The Journal of Urology. – 2012. – Vol. 187. № 4. – P. e120–e121.
24. Kinnaird A., Dromparis P., Saleme B., Gurtu V., Watson K., Paulin R., Zervopoulos S., Stenson T., Sutendra G., Pink D. B., Carmine-Simmen K., Moore R., Lewis J. D., Michelakis E. D. Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase // European Urology. – 2016. – Vol. 69. № 4. – P. 734–744.
25. Kluza J., Corazao-Rozas P., Touil Y., Jendoubi M., Maire C., Guerreschi P. et al. Inactivation of the HIF-1alpha/ PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants // Cancer Research. – 2012. – Vol. 72. № 19. – P. 5035–5047.
26. Kwitniewski M., Moan J., Juzeniene A. Metabolic-targeted therapy with dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy // Photochemical & Photobiological Sciences. – 2011. – Vol. 10. № 1. – P. 25–28.
27. Li T., Schultz I., Keys D. A., Campbell J. L., Fisher J. W. Quantitative evaluation of dichloroacetic acid kinetics in human – a physiologically based pharmacokinetic modeling investigation // Toxicology. – 2008. – Vol. 245. № 1–2. – P. 35–48.
28. Ludvik B., Peer G., Berzlanovich A., Stifter S., Graf H. Effects of dichloroacetate and bicarbonate on haemodynamic parameters in healthy volunteers // Clinical Science. – 1991. – Vol. 80. № 1. – P. 47–51.
29. Madhok B. M., Yeluri S., Perry S. L., Hughes T. A., Jayne D. G. Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells // British Journal of Cancer. – 2010. – Vol. 102. № 12. – P. 1746–1752.
30. Michelakis E. D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E. et al. Metabolic modulation of glioblastoma with dichloroacetate // Science Translational Medicine. – 2010. – Vol. 2. № 31. – P. 31ra34.
31. Michelakis E. D., Webster L., Mackey J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer // British Journal of Cancer. – 2008. – Vol. 99. № 7. – P. 989–994.
32. Ohashi T., Akazawa T., Aoki M., Kuze B., Mizuta K., Ito Y., Inoue N. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity // International Journal of Cancer. – 2013. – Vol. 133. № 5. – P. 1107–1118.
33. Olszewski U., Poulsen T. T., Ulsperger E., Poulsen H. S., Geissler K., Hamilton G. In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds // Clinical Pharmacology: Advances and Applications. – 2010. – Vol. 2. – P. 177–183.
34. Pfeffer G., Majamaa K., Turnbull D. M. et al. Treatment for mitochondrial disorders // Cochrane Database of Systematic Reviews. – 2012. – № 4. – CD004426.
35. Rajendran A., Bansal D., Marwaha R. K., Singhi S. C. Tumor lysis syndrome // The Indian Journal of Pediatrics. – 2013. – Vol. 80. № 1. – P. 50–54.
36. Ribes G., Valette G., Loubatieres-Mariani M. -M. Metabolic effects of sodium dichloroacetate in normal and diabetic dogs // Diabetes. – 1979. – Vol. 28. № 9. – P. 852–857.
37. Roh J. - L., Park J. Y., Kim E. H., Jang H. J., Kwon M. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer // Cancer Letters. – 2016. – Vol. 371. № 1. – P. 20–29.
38. Rozier M. D., Zata V. J., Ellsworth M. L. Lactate interferes with ATP release from red blood cells // The American Journal of Physiology. Heart and Circulatory Physiology. – 2007. – Vol. 292. № 6. – P. H3038-H3042.
39. Saed G. M., Fletcher N. M., Jiang Z. L., Abu-Soud H. M., Diamond M. P. Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress // Reproductive Sciences. – 2011. – Vol. 18. № 12. – P. 1253–1261.
40. Shahrzad S., Lacombe K., Adamcic U., Minhas K., Coomber B. L. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia // Cancer Letters. – 2010. – Vol. 297. № 1. – P. 75–83.
41. Shen H., Decollogne S., Dilda P. J., Hau E., Chung S. A., Luk P. P., Hogg P. J., McDonald K. L. Dual-targeting of aberrant glucose metabolism in glioblastoma // Journal of Experimental & Clinical Cancer Research. – 2015. – Vol. 34. № 1. – Article 14.
42. Shen Y., Fan H., Ou D., Liao S., Cheng A. et al. Dichloroacetate (DCA) enhances activities of sorafenib against hepatocellular carcinoma (HCC) via modulation of aberrant cellular metabolism of HCC cells // Molecular Cancer Therapeutics. – 2009. – Vol. 8. № 12 (Suppl.). – Abstract B97.
43. Shen Y. C., Ou D. L., Hsu C., Lin K. L., Chang C. Y., Lin C. Y. et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma // British Journal of Cancer. – 2013. – Vol. 108. № 1. – P. 72–81.
44. Stacpoole P. W. Review of the pharmacologic and therapeutic effects of diisopropylammonium dichloroacetate (DIPA) // The Journal of Clinical Pharmacology. – 1969. – Vol. 9. № 5. – P. 282–291.
45. Stacpoole P. W. The pharmacology of dichloroacetate // Metabolism – Clinical and Experimental. – 1989. – Vol. 38. № 11. – P. 1124–1144.
46. Stacpoole P. W. Treatment of hyperlipoproteinemia with a dichloroacetate salt // United States Patent Number: 4,122,188. – Date of Patent: Oct. 24, 1978. – Appl. №: 828, 677. – Filed: Aug. 29, 1977.
47. Stacpoole P. W., Dunbar E. M., Shroads A. L., Coats B. S., Langaee T. Predictability of glutathione transferase zeta 1 haplotype on kinetics of dichloroacetate in human trials // Drug Metabolism Reviews. – 2011. – Vol. 43. – Suppl. 2. – P. 181–182.
48. Stacpoole P. W., Henderson G. N., Yan Z., Cornett R., James M. O. Pharmacokinetics, metabolism and toxicology of dichloroacetate // Drug Metabolism Reviews. – 1998. – Vol. 30. № 3. – P. 499–539.
49. Stacpoole P. W., Kerr D. S., Barnes C., Bunch S. T., Carney P. R., Fennell E. M. et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children // Pediatrics. – 2006. – Vol. 117. № 5. – P. 1519–1531.
50. Stacpoole P. W., Nagaraja N. V., Hutson A. D. Efficacy of dichloroacetate as a lactate- lowering drug // Journal of Clinical Pharmacology. – 2003. – Vol. 43. № 7. – P. 683–691.
51. Strum S. B., Adalsteinsson O., Black R. R., Segal D., Peress N. L., Waldenfels J. Case report: sodium dichloroacetate (DCA) inhibition of the "Warburg effect" in a human cancer patient: complete response in non-Hodgkin's lymphoma after disease progression with rituximab-CHOP // Journal of Bioenergetics and Biomembranes. – 2013. – Vol. 45. № 3. – P. 307–315.
52. Sun R. C., Board P. G., Blackburn A. C. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells // Molecular Cancer. – 2011. – Vol. 10. – Article 142.
53. Sun R. C., Fadia M., Dahlstrom J. E., Parish C. R., Board P. G., Blackburn A. C. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo // Breast Cancer Research and Treatment. – 2010. – Vol. 120. № 1. – P. 253– 260.
54. Tong J., Xie G., He J., Li J., Pan F., Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer // Journal of Biomedicine & Biotechnology. – 2011. – Vol. 2011. – Article ID 740564.
55. Valauri-Orton A., Bschorer F., Bernd K. K. Dichloroacetate decreases cell health and activates oxidative stress defense pathways in rat alveolar type II pneumocytes // BioMed Research International. – 2015. – Vol. 2015. – Article ID 129031.
56. Vella S., Conti M., Tasso R., Cancedda R., Pagano A. Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells // International Journal of Cancer. – 2012. – Vol. 130. № 7. – P. 1484–1493.
57. Vissing J., Gansted U., Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis // Annals of Neurology. – 2001. – Vol. 49. № 5. – P. 672–676.
58. Wargovich T. J., MacDonald R. G., Hill J. A., Feldman R. L., Stacpoole P. W., Pepine C. J. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease // The American Journal of Cardiology. – 1988. – Vol. 61. № 1. – P. 65–70.
59. Washington J. T., Quintyne N. J. Dichloroacetate induces different rates of cell death in cancer and noncancer cell lines in vitro // Tumori. – 2012. – Vol. 98. № 1. – P. 142–151.
60. Wong J. Y., Huggins G. S., Debidda M., Munshi N. C., De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells // Gynecologic Oncology. – 2008. – Vol. 109. № 3. – P. 394–402.
61. Xiao H., Yan L., Zhang Y., Qi R., Li W., Wang R. et al. A dual-targeting hybrid platinum (IV) prodrug for enhancing efficacy // Chemical Communications. – 2012. – Vol. 48. № 87. – P. 10730– 10732.
62. Xiao L., Li X., Niu N., Qian J., Xie G., Wang Y. Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24 // Molecular and Cellular Biochemistry. – 2010. – Vol. 340. № 1. – P. 31–40.
63. Xie J., Wang B. S., Yu D. H., Lu Q., Ma J., Qi H. et al. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells // International Journal of Oncology. – 2011. – Vol. 38. № 2. – P. 409–417.
64. Xue X., You S., Zhang Q., Wu Y., Zou G. Z., Wang P. C. et al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction // Molecular Pharmaceutics. – 2012. – Vol. 9. № 3. – P. 634–644.
65. Zajac J., Kostrhunova H., Novohradsky V., Vrana O., Raveendran R., Gibson D., Kasparkova J., Brabec V. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin // Journal of Inorganic Biochemistry. – 2016. – Vol. 156. – P. 89–97.
66. Zhang N., Palmer A. F. Development of a dichloroacetic acid-hemoglobin conjugate as a potential targeted anti-cancer therapeutic // Biotechnology and Bioengineering. – 2011. – Vol.108. № 6. – P. 1413–1420.
Review
For citations:
TSYMBALYUK I.Y., MANUILOV A.M., POPOV K.A., KHUBIEVA F.U., GILEVA E.E. THE BIOLOGICAL ACTIVITY OF SODIUM DICHLOROACETATE AND ITS EFFECTIVENESS DURING THE EXPERIMENTAL CLINICAL STUDIES. Kuban Scientific Medical Bulletin. 2017;1(2):151-162. (In Russ.) https://doi.org/10.25207/1608-6228-2017-2-151-162
Views:
13613
Email this article 